Botanical species · safety record

Piper auritum

The EFSA Compendium of Botanicals holds 22 constituent measurements and 2 adverse-effect records for Piper auritum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Piper auritum Kunth

22Constituent measurements

2Safety records

11Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
1,8-cineole	Leaves	Essential oil	—	GC-MS	No resolvable identifier
Aporphine alkaloids	Unspecified	—	—	Unspecified	No resolvable identifier
Camphor	Unspecified	Essential oil	1.09 Percent	GC-MS	No resolvable identifier
Camphor	Flowering top	Essential oil	3.2 Percent	GC-MS	No resolvable identifier
Camphor	Leaves	Essential oil	—	GC-MS	No resolvable identifier
Camphor	Seed	Essential oil	3.3 Percent	GC-MS	No resolvable identifier
Cepharadione b	Unspecified	—	—	Unspecified	No resolvable identifier
Elemicin	Leaves	Essential oil	—	GC-MS	No resolvable identifier
Eugenol	Leaves	Essential oil	—	GC-MS	No resolvable identifier
Myrcene	Leaves	Essential oil	—	GC-MS	No resolvable identifier
Myristicin	Unspecified	Essential oil	4.3 Percent	GC-MS	No resolvable identifier
Myristicin	Leaves	Essential oil	—	GC-MS	No resolvable identifier
Safrole	Seed	Essential oil	67.4 Percent	GC-MS	No resolvable identifier
Safrole	Leaves	Solvent extraction	≤ 65.7 Percent	GC-MS	No resolvable identifier
Safrole	Leaves	Solvent extraction	≥ 60.5 Percent	GC-MS	No resolvable identifier
Safrole	Leaves	Essential oil	≤ 39.42 Percent	GC-MS	No resolvable identifier
Safrole	Leaves	Essential oil	64.5 Percent	GC-MS	No resolvable identifier
Safrole	Leaves	Essential oil	70 Percent	GC-MS	No resolvable identifier
Safrole	Leaves	Essential oil	≥ 33.93 Percent	GC-MS	No resolvable identifier
Safrole	Unspecified	Essential oil	68.89 Percent	GC-MS	No resolvable identifier
Safrole	Unspecified	Essential oil	93.2 Percent	GC-MS	No resolvable identifier
Safrole	Flowering top	Essential oil	93.2 Percent	GC-MS	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
None	—	Leaves	Solvent extraction	House mouse (as animal)	Acute toxicity	No resolvable identifier
None	—	Leaves	Solvent extraction	House mouse (as animal)	Acute toxicity	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Ciccio, Jose F. Volatile components of Piper auritum (Piperoceae) spikes from Costa Rica. Ingenieria y ciencia quimica, 1996, p. 78-79.
McBurnett, B.G., Chavira, A.A., L�pez, A.C., Mosso, J., Collins, S.M. Analysis of Piper auritum: A traditional hispanic herb. ACS Symposium Series, 2007, vol. 946, p. 67-76.
Tucker, AO., Maciarello, MJ., Contis, ET., Ho, CT., Mussinan, CJ., Parliment, TH., Shahidi, F., Spanier, AM. Some toxic culinary herbs in North America. Food flavors: formation, analysis, and packaging influences, 1998, vol. 40, p. 401-414.
Pino, Jorge A., Rosado, Aristides., Rodriguez, Mayra., Garcia, Dinah. Composition of leaf oil of Piper auritum H.B.K. grown in Cuba. Journal of essential oil research, 1998, p. 333-334.
Gupta, Mahabir P., Arias, Tomas D., Williams, Norris H., Bos, R., Tattje, D. H. E. Safrole, the main component of the essential oil from Piper auritum of Panama. Journal of Natural Products, 1985.
Caballero-Gallardo, Karina., Olivero-Verbel, Jesus., Pino-Benitez, Nayive., Stashenko, Elena E. Chemical composition and bioactivity of Piper auritum and P-multiplinervium essential oils against the red flour beetle, Tribolium castaneum (Herbst) . Boletin latinoamericano y del caribe de plantas medicinales y aromaticas, 2014, vol. 13, no. 1, p. 10-19.
Vogler, Bernhard., Noletto, Joseph A., Haber, William A., Setzer, William N. Chemical constituents of the essential oils of three Piper species from Monteverde, Costa Rica. Journal of Essential Oil-Bearing Plants, 2006, p. 230-238.
Wishart, DS., Jewison, T., Guo, AC., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., Bouatra, S., Sinelnikov, I., Arndt, D., Xia, J., Liu, P., Yallou, F., Bjorndahl, T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, R., Scalbert, A. Cepharadione B (HMDB30391).. Human metabolome database, 2012, vol. 3.0.
Parra, AL., Yhebra, RS., Sardinas, IG., Buela, LI. Comparative study of the assay of Artemia salina L. and the estimate of the medium lethal dose (LD50 value) in mice, to determine oral acute toxicity of plant extracts. PHYTOMEDICINE, 2001, vol. 8, no. 5, p. 395-400.
Vega Montalvo, R., Lagarto Parra, A. Evaluaci�n del efecto antiinflamatorio del extracto de Piper auritum H.B.K. y toxicidad aguda oral. Revista cubana de plantas medicinales, 1999, vol. 4, no. 1, p. 11-14.
Wishart, DS., Jewison, T., Guo, AC., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., Bouatra, S., Sinelnikov, I., Arndt, D., Xia, J., Liu, P., Yallou, F., Bjorndahl, T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, R., Scalbert, A. Cepharadione A (HMDB34364).. Human metabolome database, 2012, vol. 3.0.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature